To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations
Chiglitazar is a promising new-generation insulin sensitizer with low reverse effects for the treatment of type II diabetes mellitus (T2DM) and has shown activity as a nonselective pan-agonist to the human peroxisome proliferator-activated receptors (PPARs) (i.e., full activation of PPARγ and a part...
Saved in:
Main Authors: | Holli-Joi Sullivan, Xiaoyan Wang, Shaina Nogle, Siyan Liao, Chun Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2020/5314187 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Pan-Cancer
by: Runzhi Huang, et al.
Published: (2020-01-01) -
The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
by: M. C. Thomas, et al.
Published: (2012-01-01) -
Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
by: Jihan Youssef, et al.
Published: (2002-01-01) -
Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?
by: Ahmad Aljada, et al.
Published: (2009-01-01) -
Peroxisome Proliferator-Activated Receptors in Lung Cancer
by: Venkateshwar G. Keshamouni, et al.
Published: (2007-01-01)